Clinical trials
Targeted Therapy clinical trials
Below are recruiting targeted therapy clinical trials, each written for real people, not researchers. We’re tracking 292 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06691061Recruiting
Comparing advanced treatments for ulcerative colitis after anti-TNF therapy
This trial compares three types of medications (vedolizumab, ustekinumab, and JAK inhibitors) in people with ulcerative colitis who have already tried an anti-TNF drug but still have active disease. The goal is to see which treatment works best as a second option.
Mialn, ItalyAges 18 years+ - NCT07637877RecruitingPhase 2
Treatments to boost immune recovery in HIV
This study tests new treatments to help people with HIV who have low CD4 counts despite antiretroviral therapy. It aims to improve immune function and reduce the risk of infections.
Beijing, Beijing MunicipalityAges 18–60 - NCT06700369Recruiting
Lowering chemo with targeted therapy for HER2+ breast cancer
This study looks at whether using targeted therapy can reduce the amount of chemotherapy needed before surgery for HER2-positive breast cancer. It aims to find a safer, equally effective treatment plan.
Beijing, Beijing MunicipalityAges Any age - NCT06711055Recruiting
Taxane plus targeted therapy for early HER2-positive breast cancer
This trial tests a taxane chemotherapy combined with a targeted therapy for women with early-stage, HER2-positive breast cancer that has not spread to lymph nodes. It aims to provide a tailored treatment based on tumor size and risk factors.
Beijing, Beijing MunicipalityAges Any age - NCT06722612Recruiting
Chemo plus targeted therapy for high-risk HER2+ early breast cancer
This trial tests whether combining chemotherapy with targeted therapy works better for women with high-risk, HER2 positive early breast cancer that hasn't spread to lymph nodes. If you've had surgery and your tumor fits certain high-risk features, you may be eligible to join.
Beijing, Beijing MunicipalityAges Any age - NCT06742021Recruiting
MRI test to predict immune therapy response in lung cancer
This trial uses a special MRI technique (4D FreeBreathing) to see if it can predict how well immune therapy or targeted therapy works for your lung cancer. It may help doctors choose the best treatment for you more quickly.
Kunming, YunnanAges 18–75 - NCT07528716RecruitingPhase 3
AI-guided treatment for HER2-positive breast cancer
This trial tests whether an artificial intelligence model can help doctors choose the best targeted therapy before surgery for HER2-positive breast cancer (a type of breast cancer with a protein called HER2). The goal is to improve how well the treatment works and reduce side effects.
ShanghaiAges 18–75 - NCT07530380RecruitingEarly Phase 1
CAR T-cell therapy for treatment-resistant autoimmune hemolytic anemia
This trial tests a new type of cell therapy called UCAR T-cells, which are immune cells engineered to target and destroy the B cells causing your body to attack its own red blood cells. It's designed for patients whose autoimmune hemolytic anemia hasn't responded to at least 3 standard treatments.
HefeiAges 10 years+ - NCT07499271RecruitingPhase 2
Targeted therapy for newly diagnosed DLBCL with TP53 mutation
This trial tests a targeted therapy designed to match the specific genetic subtype of DLBCL that has a TP53 mutation. It may offer a more effective treatment option for people whose cancer has this genetic change.
Suzhou, JiangsuAges 18–70 - NCT06718257Recruiting
Chemo with immunotherapy and targeted drugs for bile duct cancer
This trial tests whether adding immunotherapy and targeted therapy to standard chemotherapy can help treat intrahepatic cholangiocarcinoma (a type of bile duct cancer). It is for patients who are starting treatment with one of two specific chemo regimens, possibly combined with the new drugs.
Hangzhou, ZhejiangAges 18 years+ - NCT05200260RecruitingPhase 2
Surgery plus maintenance medicines for advanced ovarian cancer
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
FoshanAges 18 years+ - NCT06542796Recruiting
Classifying treatment effects for advanced liver cancer
This study looks at how well different treatments work for people with advanced liver cancer. It may help doctors better understand which treatments are most effective for patients like you.
Hangzhou, ZhejiangAges 18–75 - NCT06824714Recruiting
Predicting blood vessel damage in large vessel vasculitis
This study uses PET and MRA scans to predict damage to large blood vessels in people who have or may have large vessel vasculitis (LVV). It aims to find at-risk patients early so they can get better care. You'll need to be willing to have both scans and come back for long-term check-ups.
Nanjing, JiangsuAges 18 years+ - NCT06771960Recruiting
Targeted therapy before surgery for EGFR lung cancer
This trial looks at how well a targeted therapy works before surgery for people with EGFR-mutated non-small cell lung cancer. It aims to understand the link between a heart rhythm measure (RVT) and patient outcomes.
Guangzhou, GuangdongAges 18–80 - NCT07376174Recruiting
HER2-positive breast cancer and dual-target therapy study
This study looks at how well a combination of two targeted drugs (trastuzumab and pertuzumab) works for people with HER2-positive breast cancer that hasn't spread. It aims to understand how HER2 levels affect treatment outcomes after surgery.
Jinan, ShandongAges 18 years+ - NCT07350837RecruitingEarly Phase 1
CAR-T therapy for highly sensitized kidney transplant patients
This trial tests a new CAR-T therapy that targets immune cells to reduce harmful antibodies in highly sensitized kidney transplant candidates. The goal is to help your body accept a kidney from a donor that would otherwise be rejected.
Wuhan, HubeiAges 18–65 - NCT07347951RecruitingPhase 2
New drug combo for rectal cancer patients who want to save their anus
This trial tests a combination of short-course radiation, chemotherapy, and two targeted drugs (Serplulimab and Bevacizumab) for people with a specific type of rectal cancer. It aims to see if this treatment can help shrink the tumor enough to avoid surgery and keep the anus.
Wenzhou, ZhejiangAges 18–75 - NCT07340398RecruitingPhase 2
Testing new drug combos for HER2-positive breast cancer not responding to first therapy
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
HangzhouAges 18–75 - NCT07309718Recruiting
Stroke Risk Assessment for Brain Artery Narrowing
This study looks at a new way to measure stroke risk in people with a specific type of brain artery narrowing (atherosclerosis) in the front part of the brain. You might participate if you have this condition and are willing to have imaging tests and take standard medicines.
Beijing, Xicheng DistrictAges 18–80 - NCT07315087RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
TianjinAges 18 years+ - NCT07305116RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
Hangzhou, ZhejiangAges 3 years+ - NCT06031727RecruitingEarly Phase 1
CRISPR gene therapy for wet age-related macular degeneration
This trial tests a new CRISPR-based treatment for wet age-related macular degeneration (AMD). It aims to stop vision loss by targeting the cause of abnormal blood vessel growth in the eye. This study is for people who have already tried anti-VEGF injections but might not be responding well enough.
Shanghai, Shanghai MunicipalityAges 50–80 - NCT07250269RecruitingPhase 1
CAR-T therapy for AL amyloidosis
This trial tests a new CAR-T cell therapy (GC012F) that targets two proteins, CD19 and BCMA, on abnormal plasma cells. It's for people with AL amyloidosis who have already tried at least one treatment.
BeijingAges 18 years+ - NCT05013255RecruitingPhase 2
Pioglitazone to treat fatigue in hormone-positive breast cancer
This Phase 2 study tests whether pioglitazone can reduce fatigue in people with certain types of breast cancer. You may be eligible if your cancer is estrogen- and progesterone-positive (ER+/PR+) and you plan surgery soon.
Morgantown, West VirginiaAges 18 years+
Hear when a new Targeted Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for targeted therapy?
- Yes. Clin2 currently lists 292 recruiting targeted therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a targeted therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a targeted therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.